Background
==========

Non-small-cell lung cancer (NSCLC), mainly divided into adenocarcinoma (AD) and squamous cell carcinoma (SCC) pathologically,[@b1-cmar-10-1449],[@b2-cmar-10-1449] is the predominant form of lung cancer and accounts for the majority of cancer deaths worldwide.[@b3-cmar-10-1449] Despite much progress being achieved in early detection and treatment, the 5-year survival rate for NSCLC patients is still only 5%--20%.[@b4-cmar-10-1449] Thus, it is an urgent medical need to develop more sensitive diagnostic methods and novel biomarkers, especially for patients with recurrent cancers.[@b5-cmar-10-1449]--[@b7-cmar-10-1449]

Due to tumor evolution and heterogeneity, traditional tissue biopsy-based cancer diagnostic procedures have limitations in their assessment for cancer diagnosis, genotyping, and prognosis.[@b8-cmar-10-1449] Therefore, clinicians and scientists have tried to use blood-based liquid biopsies as a potential alternative diagnostic method for NSCLC patients.[@b9-cmar-10-1449],[@b10-cmar-10-1449]

Liquid biopsy, including tumor-educated blood platelets (TEPs), exosomes, circulating cell-free tumor DNA, and circulating tumor cells, could offer earlier and more convenient diagnosis for patients with NSCLC. Additionally, these techniques are less invasive and may provide a more comprehensive characterization for NSCLC.[@b11-cmar-10-1449]-[@b13-cmar-10-1449] The plasma is a pool of cells or cell products (DNA, RNA, and proteins) derived from the tumor or circulating tumor cells and stromal cells of the tumor microenvironment. The analysis of these blood components can, therefore, provide a comprehensive real-time information of the tumor-associated changes in an individual cancer patient.[@b14-cmar-10-1449] However, it has been also reported that tumor-associated biomarkers released into the plasma are susceptible to degradation, while blood platelets are more stable and can offer high sensitivity for the detection of *EML4-ALK* rearrangements.[@b15-cmar-10-1449] Given the fact that blood platelets, the second most abundant cell type in peripheral blood, can take up tumor-derived microvesicles loaded with tumor-specific cellular compounds (RNA, protein, etc),[@b16-cmar-10-1449] TEPs have been proposed and currently investigated as a potential biomarker source for cancers.[@b17-cmar-10-1449]

Long noncoding RNA (lncRNA) is a group of RNA molecules that are longer than 200 nucleotides and do not encode protein,[@b18-cmar-10-1449] and they regulate gene expression through epigenetic regulation, splicing, imprinting, transcriptional regulation, and subcellular transport[@b19-cmar-10-1449] and play important roles in tumorigenesis and tumor progression.[@b20-cmar-10-1449] In recent years, aberrant lncRNA expression has been found to participate in NSCLC development and metastasis. For example, increased *HNF1A-AS1* promoted lung AD cell proliferation and metastasis through interacting with *DNMT1* and repressing E-cadherin expression.[@b21-cmar-10-1449] LncRNA metastasis-associated lung adenocarcinoma transcript 1 (*MALAT1*) is a highly conserved nuclear lncRNA, which is upregulated and can serve as a predictive marker for metastasis in lung cancer.[@b22-cmar-10-1449] These data indicated that lncRNAs play important roles in NSCLC pathogenesis, which could provide new insights into the biology of this devastating disease.

The epidermal growth factor receptor (*EGFR*), a prototype member of the type I receptor tyrosine kinase (TK) family, plays a critical role in NSCLC cell differentiation, proliferation, and treatment response. Genetic alterations of the *EGFR*, including intracellular mutations such as *19-Del*, *L858R*, *T790M*, *20-lns*, *G719X*, *S768I*, and *L861Q* and extracellular mutation *EGFRvIII*, predominantly found in ADs,[@b23-cmar-10-1449] are representative biomarkers in determining the appropriate treatment for advanced lung cancer. The identification of *EGFR* mutations provides guidance for clinical treatment with *EGFR* TK inhibitors such as gefitinib and erlotinib.[@b24-cmar-10-1449],[@b25-cmar-10-1449]

In the present study, we first screened out five lncRNAs with potential diagnostic significance from three gene expression omnibus (GEO) datasets, GSE19188, GSE30219, and GSE27262,[@b26-cmar-10-1449] which included expression information of tumor tissue from patients with AD or SCC. Next, we investigated the expression pattern and diagnostic value of five lncRNAs in platelets and plasma derived from patients with NSCLC to explore whether TEPs could enable NSCLC diagnostic and identify NSCLC types. Furthermore, we evaluated *EGFR* intracellular mutations in DNA extracted from platelets and plasma of 14 NSCLC patients who have been confirmed with *EGFR* intracellular mutations in tissue biopsy samples, and we also detected *EGFRvIII* expression within TEPs RNA for companion diagnostic of NSCLC.

Methods
=======

Platelets and plasma isolation
------------------------------

Whole-blood samples (2 mL) of NSCLC patients and healthy controls were collected from Zhongnan Hospital of Wuhan University under approval of Institutional Review Board, and written informed consent was obtained from all participants. Then, platelets and plasma were isolated from the same sample of whole blood by standard centrifugation within 24 hours to minimize detrimental effects of long-term storage at room temperature and decrease of platelet/plasma RNA quality and quantity. Three hundred microliters of platelets-rich plasma was obtained by centrifugation at room temperature for 20 min at 120 *g* to remove interference of cells. Then, platelets were isolated from the 300 µL platelet-rich plasma by centrifugation at room temperature for 20 min at 360 *g*, and resuspended in 300 µL PBS after washing twice. Plasma and platelets were frozen in parallel and stored at −80°C for further use.

GEO lung cancer gene expression data
------------------------------------

Three panels of NSCLC in NCBI GEO were used in our lncRNA screening with the accession IDs GSE19188, GSE30219, and GSE27262. Reading and processing of data were done using R package "limm", genes with adjusted *p*-value \<0.05 and fold change \>2 were identified as threshold value to judge differentially expressed lncRNAs, then we proceeded to receiver operating characteristic (ROC) analysis to screen out four lncRNAs that possessed great diagnostic value (we also added an lncRNA that possessed poor diagnostic value).

RNA isolation and cDNA synthesis
--------------------------------

Total RNA was isolated from 300 µL platelet suspension and 300 µL plasma using a Liquid Total RNA Isolation Kit (RP4002, BioTeke, Beijing, China) and eluted in 35 µL of prewarmed (65°C) elution according to the manufacturer's instruction. The concentration of RNA was measured by Nanodrop 2000 spectrophotometer (Thermo Scientific Inc, USA). Then RNA was reverse transcribed to cDNA using PrimeScript™ RT reagent kit with gDNA Eraser (RR047A, Takara, Dalian, China). Reverse transcription conditions were as follows: 42°C for 2 min, and then 37°C for 15 min, 85°C for 5 s. The cDNA was frozen at −20°C for further use.

Quantitative real-time PCR (RT-qPCR) for lncRNAs
------------------------------------------------

The expression of lncRNAs was determined on the Bio-Rad CFX96 (Bio-Rad Laboratories Inc, Hercules, CA, USA) using SYBR-Green I Premix Ex Taq following the manufacturer's instructions. The *GAPDH* was used as the endogenous control and was amplified simultaneously with target genes. The synthesized RT-qPCR primers are listed in [Table S1](https://www.dovepress.com/get_supplementary_file.php%3Ff%3D164227.pdf). The reactions were performed in a volume of 20 µL (10 µL of SYBR mix, 0.8 µL of 10 µmol sense, 0.8 µL of 10 µmol antisense, 2 µL cDNA and 6.4 µL water). The reactions started at 95°C for 5 min, followed by 42 cycles of 95°C for 30 s, 63.3°C for 30 s, and 72°C for 30 s. All experiments were carried out in duplicate for each data point. The relative gene expression level was calculated using the comparative Ct method formula 2^−ΔCt^.

DNA extraction and amplification-refractory mutation system (ARMS)-PCR for *EGFR* intracellular mutations
---------------------------------------------------------------------------------------------------------

DNA was isolated from 14 TEPs and plasma samples using QIAamp^®^ Circulating Nucleic Acid kits (QIAGEN, Hilden, Germany) eluted in 50 µL of elution according to the manufacturer's instruction; *EGFR* intracellular mutations including *19-Del*, *L858R*, *T790M*, *20-lns*, *G719X*, *S768I*, and *L861Q* were detected using an ADx-ARMS *EGFR* mutation detection kit (ADx-EG01, AmoyDx, Xiamen, China) by ARMS.

RT-PCR for *EGFRvIII*
---------------------

Samples from 110 AD, 95 SCC, and 50 healthy controls were collected and determined *EGFR*/*EGFRvIII* existence with RT-PCR in a volume of25 µLsolution (12.5 µL of AmpliTaq Gold^®^ 360 Master mix, 0.5 µL 10 µmol sense, 0.5 µL 10 µmol antisense, 2 µL cDNA, and 9.5 µL water). PCR condition is listed as follows: 95°C 5 min; 95°C 30 s, 55°C 45 s, 72°C 1 min × 42 cycles; 72°C 7 min. The RT-PCR primers are listed in [Table S1](https://www.dovepress.com/get_supplementary_file.php%3Ff%3D164227.pdf).

Statistical analysis
--------------------

Statistical analyses were performed using SPSS version 22.0 (SPSS, Chicago, IL, USA) or Prism6 (GraphPad software, La Jolla, CA, USA). Data were presented as median with interquartile range. The Shapiro--Wilk test was carried out to check the normality of the distribution. The normally distributed numeric variables were evaluated by Student's *t*-test, while non-normally distributed variables were analyzed by Mann--Whitney test. Chi-square test was used to analyze the categorical variables. One-way analysis of variance (ANOVA) or nonparametric test was used to validate the different expression levels of lncRNAs among subgroups. Statistical differences were set at \**p*\<0.05, \*\**p*\<0.01, \*\*\**p*\<0.001, and \*\*\*\**p*\<0.0001. *p*\<0.05 was considered statistically significant. To estimate the diagnostic value of the biomarkers, area under the ROC curve analysis was performed.

Results
=======

Identification of potential lncRNAs as biomarkers for NSCLC diagnosis from GEO dataset
--------------------------------------------------------------------------------------

To identify relevant datasets, we searched GEO for NSCLC expression profiling studies, and the criteria for choice of datasets are that 1) they were gene profiling studies in patients with NSCLC; 2) they used the same platform; 3) they used NSCLC tissue and normal lung tissue for comparison; and 4) they contained the information of AD or SCC. We finally narrowed down and analyzed three GEO public datasets: GSE19188 containing 45 AD, 27 SCC, and 65 normal lung tissue controls, GSE30219 containing 85 AD, 61 SCC, and 14 normal lung tissue controls, GSE27262 containing 25 AD and 25 normal lung tissue controls. Based on these three GEO datasets, we screened out five lncRNAs including *MAGI2-AS3*, *LOC100507632*, *FXF1-AS1*, *LOC100499467*, and *ZFAS1* listed in [Table 1](#t1-cmar-10-1449){ref-type="table"}. *MAGI2-AS3*, *LOC100507632*, and *FOXF1-AS1* were significantly downregulated (*p*\<0.0001 in all three GEO datasets) in NSCLC tissue, while *LOC100499467* (*p*\<0.0001 in all three GEO datasets) and *ZFAS1* (*p*\<0.05 in all three GEO datasets) were significantly upregulated. In addition, the first four lncRNAs all exhibited great diagnostic value (area under the ROC curve \[AUC\]\>0.900), while the diagnostic value for *ZFAS1* was relatively poor.

*MAGI2-AS3* and *ZFAS1* were both downregulated in NSCLC platelets and plasma
-----------------------------------------------------------------------------

To confirm the finding of bioinformatics analysis, we used 68 ADs and 33 SCCs and 60 healthy controls for detecting these five lncRNAs to test whether TEPs could serve as a liquid biopsy for tumor diagnosis. Our result indicted that we can only detect *MAGI2-AS3* and *ZFAS1* expression among five lncRNAs from TEP samples. Although *LOC100507632*, *FOXF1-AS1*, and *LOC100499467* can be detected in A549 NSCLC cell line, we cannot detect their expression because of the low abundance in 300 µL platelet suspension and 300 µL plasma ([Figure S1](https://www.dovepress.com/get_supplementary_file.php%3Ff%3D164227.pdf)). For *MAGI2-AS3*, both platelets and plasma were significantly downregulated in line with the result from GEO datasets ([Figure 1A](#f1-cmar-10-1449){ref-type="fig"}, B). The melt curve of *MAGI2-AS3* showed that the amplification specificity was good ([Figure S2A, B](https://www.dovepress.com/get_supplementary_file.php%3Ff%3D164227.pdf)). The result of agarose gel electrophoresis revealed that the amplification product was the target gene *MAGI2-AS3* and endogenous gene *GAPDH* ([Figure S2C](https://www.dovepress.com/get_supplementary_file.php%3Ff%3D164227.pdf)). In addition, platelets' *MAGI2-AS3* expression was positively correlated with plasma *MAGI2-AS3*. Spearman's correlation analysis showed that the correlation coefficient was 0.738 (*p*\<0.0001; [Figure 1C](#f1-cmar-10-1449){ref-type="fig"}). *ZFAS1* was significantly downregulated in platelets and plasma samples from NSCLC, which was different from the result from GEO datasets ([Figure 1D](#f1-cmar-10-1449){ref-type="fig"}, E), and spearman correlation analysis showed that the correlation coefficient was 0.751 (*p*\<0.0001; [Figure 1F](#f1-cmar-10-1449){ref-type="fig"}). The melt curve ([Figure S2D, E](https://www.dovepress.com/get_supplementary_file.php%3Ff%3D164227.pdf)) and result of agarose gel electrophoresis ([Figure S2F](https://www.dovepress.com/get_supplementary_file.php%3Ff%3D164227.pdf)) both showed that the amplification specificity was good. Based on the results of *MAGI2-AS3* and *ZFAS1*, we proposed that TEPs could also detect tumor biomarkers the same as that using plasma to a certain extent.

Correlation between the expression level of *MAGI2-AS3* and *ZFAS1* and clinical parameters of NSCLC in platelets and plasma
----------------------------------------------------------------------------------------------------------------------------

According to the median value of relative lncRNA expression in NSCLC platelets and plasma, 101 NSCLC patients were correspondently classified into two groups; in platelets (plasma), relative high group: expression ratio ≥ median, and relative low group: expression ratio \< median. As presented in [Table 2](#t2-cmar-10-1449){ref-type="table"}, all clinicopathologic data were divided into these two groups based on different grouping criteria and were analyzed by chi-squared test. The clinicopathologic relevance analysis of NSCLC patients demonstrated that the *MAGI2-AS3* expression significantly correlated with tumor--node--metastasis (TNM) stage (*p*=0.001 in platelets, *p*=0.003 in plasma), lymph-node metastasis (*p*=0.016 in platelets, *p*=0.023 in plasma), and distant metastasis (*p*=0.045 in platelets, *p*=0.045 in plasma), while *ZFAS1* level was only correlated with TNM stage (*p*=0.005 in platelets, *p*=0.044 in plasma).

Diagnostic value of *MAGI2-AS3* and *ZFAS1* analysis in AD and SCC
------------------------------------------------------------------

ROC curve analysis was used to evaluate the predicting diagnosis value of lncRNAs for NSCLC. ROC was designed to use two models: AD vs controls, SCC vs controls. AUCs of the platelets and plasma *MAGI2-AS3* were 0.853 (95% CI=0.789--0.918, *p*\<0.0001) and 0.866 (95% CI=0.802--0.929, *p*\<0.0001) in AD ([Figure 2A](#f2-cmar-10-1449){ref-type="fig"}), 0.892 (95% CI=0.819--0.965, *p*\<0.0001), and 0.887 (95% CI=0.813--0.961, *p*\<0.0001) in SCC ([Figure 2B](#f2-cmar-10-1449){ref-type="fig"}), respectively. As for *ZFAS1*, AUCs of platelets and plasma were 0.780 (95% CI=0.701--0.858, *p*\<0.0001) and 0.806 (95% CI=0.731--0.881, *p*\<0.0001) in AD ([Figure 2C](#f2-cmar-10-1449){ref-type="fig"}), and 0.744 (95% CI=0.641--0.848, *p*\<0.0001) and 0.770 (95% CI=0.663--0.878, *p*\<0.0001) in SCC ([Figure 2D](#f2-cmar-10-1449){ref-type="fig"}). Of course, combination of two lncRNAs possessed a better ability for discrimination between NSCLC and controls, both in platelets and plasma, and the AUCs of the combined *MAGI2-AS3* and *ZFAS1* were 0.908 (95% CI=0.853--0.963, *p*\<0.0001) in platelets and 0.890 (95% CI=0.834--0.946, *p*\<0.0001) in plasma of AD ([Figure 2E](#f2-cmar-10-1449){ref-type="fig"}). The AUCs of the combined *MAGI2-AS3* and *ZFAS1* were 0.919 (95% CI=0.848--0.990, *p*\<0.0001) in platelets and 0.902 (95% CI=0.833--0.972, *p*\<0.0001) in plasma of SCC ([Figure 2F](#f2-cmar-10-1449){ref-type="fig"}). As for the AUCs of combinations, please see details in [Table S2](https://www.dovepress.com/get_supplementary_file.php%3Ff%3D164227.pdf).

*EGFR* intracellular mutations detection with platelets and plasma DNA
----------------------------------------------------------------------

Fourteen NSCLC patients with AD were diagnosed with *EGFR* intracellular mutations with conventional tissue analysis. We extracted DNA of platelets and corresponding plasma from the 14 patients and detected *EGFR* intracellular mutations. Three plasma samples (NO. 6, NO. 11, and NO. 12 listed in [Table S3](https://www.dovepress.com/get_supplementary_file.php%3Ff%3D164227.pdf)) showed positive result in accordance with the result of tissue while there was no positive result in platelets ([Figure 3](#f3-cmar-10-1449){ref-type="fig"}). As for negative result and basic information of 14 patients, please see summary in [Table S3](https://www.dovepress.com/get_supplementary_file.php%3Ff%3D164227.pdf).

Platelets and plasma from NSCLC patients contain mRNA *EGFRvIII*
----------------------------------------------------------------

To determine whether circulating blood platelets and plasma isolated from NSCLC patients contain the RNA biomarker *EGFRvIII*, we compared platelets and plasma from 110 ADs and 95 SCCs to 50 healthy people. Among 205 NSCLC patients, *GAPDH* was detected in all blood platelets and plasma samples, and *EGFRvIII* was detected in three (one in ADs and two in SCC) blood platelets and the corresponding plasma samples ([Figure 4A](#f4-cmar-10-1449){ref-type="fig"}, B). In addition, among 50 healthy people, none of the blood platelets and plasma samples detected *EGFRvIII* expression, but *GAPDH* was detected in all blood platelets and plasma samples ([Figure 4C](#f4-cmar-10-1449){ref-type="fig"}, D). Our data suggested that *EGFRvIII* can also be detected in blood platelets and there was no difference with detection in plasma. To verify whether *EGFRvIII* expression of platelets was contaminated by plasma, we performed the following analysis. First, we mixed the *EGFRvIII*-positive plasma and *EGFRvIII*-negative platelets, then separated platelets and detected *EGFRvIII* expression, and the result showed that there was not *EGFRvIII* expression in platelets ([Figure S3A](https://www.dovepress.com/get_supplementary_file.php%3Ff%3D164227.pdf)). Second, we mixed the *EGFRvIII*-positive platelets and *EGFRvIII*-negative plasma, then separated plasma and detected *EGFRvIII* expression, and the result showed that there was not *EGFRvIII* expression in plasma ([Figure S3B](https://www.dovepress.com/get_supplementary_file.php%3Ff%3D164227.pdf)). Taken together, these results suggested that the *EGFRvIII* expression we detected was specific to platelets.

Discussion
==========

For decades, systematic empirical research on NSCLC has identified some prognostic factors and several biomarkers.[@b27-cmar-10-1449] However, the prognosis of NSCLC remains quite poor and the 5-year survival rate for NSCLC patients is low, because most patients are diagnosed at an advanced stage of NSCLC. Recently, the clinical application of liquid biopsy in NSCLC progressively proved a pivotal tool for screening and early detection of cancer,[@b28-cmar-10-1449] including TEPs, exosomes, circulating cell-free tumor DNA, and circulating tumor cells.

Here, we have examined the use of TEPs and plasma for a noninvasive assessment of lncRNAs and found that TEP is also a promising biosource similar to plasma. We investigated the clinical value of *MAGI2-AS3*, *LOC100507632*, *FOXF1-AS1*, *LOC100499467*, and *ZFAS1*. However, we could not detect *LOC100507632*, *FOXF1-AS1*, and *LOC100499467* which might be due to the low abundance in platelets and plasma, suggesting that not all of the lncRNAs can be detected in platelets. As for *MAGI2-AS3*, NSCLC patient platelets and plasma were significantly downregulated in line with the results from GEO. For *ZFAS1*, previous study[@b29-cmar-10-1449] suggested that *ZFAS1* is significantly downregulated in human breast cancer, where it serves as a tumor suppressor gene in tumorigenesis and progression, while another study[@b30-cmar-10-1449] showed that *ZFAS1* is frequently amplified in hepatocellular carcinoma and functions as an oncogene. Thus, the roles of *ZFAS1* in cancers are complex and might play a dual role depending on the tumor. It has previously been demonstrated that other small noncoding RNAs, such as microRNAs, can play a dual role as an oncogene or a tumor suppressor gene according to the cellular context.[@b31-cmar-10-1449] In addition, piRNAs can also play a dual role depending on the tumor. For example, piR-823 has been shown to act as a tumor suppressor in gastric cancer[@b32-cmar-10-1449] and as an oncogene in multiple myeloma.[@b33-cmar-10-1449] In our study, we found that *ZFAS1* was significantly downregulated in platelets and plasma, which was in contrast to the high expression in NSCLC tissue samples as demonstrated in previous study,[@b34-cmar-10-1449] and this phenomenon might be explained by the expression of *ZFAS1* detected in plasma and platelets which could have come from circulating cells rather than from tumor cells. Meanwhile, we analyzed the diagnostic value of *ZFAS1* and *MAGI2-AS3* and found that molecular interrogation of platelet lncRNA *ZFAS1* and *MAGI2-AS3* can offer valuable diagnostics information for NSCLC patients analyzed, of both MAGI2-AS3 (AUC is 0.853 in AD and 0.892 in SCC) and *ZFAS1* (AUC is 0.780 in AD and 0.744 in SCC). More importantly, combination of two lncRNAs possessed a better ability for discrimination between NSCLC and controls. We also analyzed the correlation between plasma lncRNA and platelet lncRNA, and we found that there was moderate correlation between both *MAGI2-AS3* (*r*=0.738, *p*\<0.0001) and *ZFAS1* (*r*=0.751, *p*\<0.0001). Furthermore, we found the correlation between the two lncRNAs' level and the clinicopathologic characteristics of the 101 NSCLC cancer patients and found that the expression level of *ZFAS1* is negatively correlated to the TNM stage while *MAGI2-AS3* expression significantly correlated with TNM stage, lymph-node metastasis, and distant metastasis. These findings suggested that the use of TEPs as a biosource to diagnose cancer may enable earlier diagnosis of cancer, improve convenience for NSCLC patients, and ultimately serve as supplement for clinical oncologic decision-making.

TEP is an emerging source for liquid biopsy, confrontation of platelets with tumor cells through transfer of tumor-associated biomolecules and results in the sequestration of such biomolecules,[@b35-cmar-10-1449],[@b36-cmar-10-1449] as shown in [Figure 5](#f5-cmar-10-1449){ref-type="fig"}. Numerous studies have emphasized the role of platelets in tumor biology, from a diagnostic standpoint of view, and TEPs carry important tumor molecular signature, with the potential to be used as a viable biosource for companion diagnostics and therapy selection.

In the present study, we extracted DNA of 14 platelets and plasma samples to detect *EGFR* intracellular mutations including *19-Del*, *L858R*, *T790M*, *20-lns*, *G719X*, *S768I*, and *L861Q* by ARMS; our data suggested that only three plasma samples could detect EGFR mutation in accordance with tissue while there was no positive result in platelets, which also indicated there was no contamination of platelet DNA by plasma DNA, and the reasons that we analyzed to explain it are as follows: first, DNA in the blood of cancer patients is derived from cells that disintegrate by necrosis and apoptosis in expanding tumor tissue,[@b37-cmar-10-1449] and this contributed to the results of plasma that were in accordance with the tissue; second, platelets reserve megakaryocyte-derived cytoplasmic pre-mRNA, some of which are spliced into mRNA,[@b38-cmar-10-1449] but most of them are microRNAs accounting for 80%;[@b39-cmar-10-1449] third, platelets can take up tumor-derived membrane vesicles such as exosomes that contain tumor-associated biomarkers;[@b16-cmar-10-1449],[@b35-cmar-10-1449] however, tumor cells might tend to exploit circulating RNA as a means to "communicate" with their regional or distal environment than the DNA derived from necrosis or apoptosis.[@b15-cmar-10-1449],[@b40-cmar-10-1449] Finally, the detection sensitivity of the ADx-ARMS *EGFR* mutation detection kit we used might be low.

Then, we shifted the focus of research to RNA of platelets. A previous study[@b16-cmar-10-1449] has shown that blood platelets isolated from glioma patients contain the tumor-associated RNA biomarker *EGFRvIII*, and *EGFRvIII* has an in-frame deletion of the extracellular domain and is found in numerous types of human tumors. As *EGFRvIII* has been reported to be tumor specific and has oncogenic potential, it has been shown to be an extremely attractive target for anticancer therapy and is more sensitive to TK inhibition.[@b41-cmar-10-1449] Duan et al[@b42-cmar-10-1449] found *EGFR-vIII* in eight of 114 (7.0%) in tissues of NSCLC patients. Therefore, we detected the *EGFRvIII* expression in TEPs and the corresponding plasma isolated from NSCLC; *EGFRvIII* was detected in three of 205 (1.5%) patients, including 2.1% (2/95) SCC and 0.9% (1/110) AD, and there was no difference with *EGFRvIII* detection between platelets and plasma. The data suggested that platelets are closely related to NSCLC and platelets contain tumor-derived RNA biomarker, which was consistent with the previous report.[@b16-cmar-10-1449]

Conclusion
==========

Our data suggested that TEP is a promising biosource to enable diagnosis of NSCLC, companion diagnostics of NSCLC, and improve convenience for NSCLC patients.
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![*MAGI2-AS2* and *ZFAS1* levels were downregulated in platelets and plasma samples derived from NSCLC patients.\
**Notes:** (**A**) *MAGI2-AS3* was downregulated in adenocarcinoma and SCC platelets than that in control platelets (*p*\<0.001). (**B**) *MAGI2-AS3* was downregulated in adenocarcinoma and SCC plasma than that in control plasma (*p*\<0.001). (**C**) Platelets' *MAGI2-AS3* level was positively correlated to the plasma *MAGI2-AS3* expression. The correlation coefficient was 0.738 (*p*\<0.0001). (**D**) *ZFAS1* was downregulated in adenocarcinoma and SCC platelets than that in control platelets (*p*\<0.001). (**E**) *ZFAS1* was downregulated in adenocarcinoma and SCC plasma than that in control plasma (*p*\<0.001). (**F**) Platelets' *ZFAS1* level was positively correlated to the plasma *ZFAS1* expression. The correlation coefficient was 0.751 (*p*\<0.0001). The relative expression level was calculated using 2^−ΔCT^ method; error bars represent the median with interquartile range. All data were analyzed using nonparametric test; NS, no significance. \*\*\**p*\<0.001, \*\*\*\**p*\<0.0001.\
**Abbreviations:** AD, adenocarcinoma; MAGI2-AS3, MAGI2 antisense RNA 3; SCC, squamous cell carcinoma; ZFAS1, ZNFX1 antisense RNA 1.](cmar-10-1449Fig1){#f1-cmar-10-1449}

![Diagnostic value of *MAGI2-AS3* and *ZFAS1* in adenocarcinoma and SCC.\
**Notes:** (**A**) The ROC curve analysis for the diagnostic value of *MAGI2-AS3* in platelets from adenocarcinoma (AUC=0.853, 95% CI=0.789--0.918, *p*\<0.0001) and (AUC=0.866, 95% CI=0.802--0.929, *p*\<0.0001) in plasma. (**B**) The ROC curve analysis for the diagnostic value of *MAGI2-AS3* in platelets from SCC (AUC=0.892, 95% CI=0.819--0.965, *p*\<0.0001) and (AUC=0.887, 95% CI=0.813--0.961, *p*\<0.0001) in plasma. (**C**) The ROC curve analysis for the diagnostic value of *ZFAS1* in platelets from adenocarcinoma (AUC=0.780, 95% CI=0.701--0.858, *p*\<0.0001) and (AUC=0.806, 95% CI=0.731--0.881, *p*\<0.0001) in plasma. (**D**) The ROC curve analysis for the diagnostic value of *ZFAS1* in platelets from SCC (AUC=0.744, 95% CI=0.641--0.848, *p*\<0.0001) and (AUC=0.770, 95% CI=0.663--0.878, *p*\<0.0001) in plasma. (**E**) The ROC curve analysis for the diagnostic value of merged *MAGI2-AS3* and *ZFAS1* in platelets from adenocarcinoma (AUC=0.908, 95% CI=0.853--0.963, *p*\<0.0001) and (AUC=0.890, 95% CI=0.834--0.946, *p*\<0.0001) in plasma. (**F**) The ROC curve analysis for the diagnostic value of merged *MAGI2-AS3* and *ZFAS1* in platelets from SCC (AUC=0.919, 95% CI=0.848--0.990, *p*\<0.0001) and (AUC=0.902, 95% CI=0.833--0.972, *p*\<0.0001) in plasma.\
**Abbreviations:** AD, adenocarcinoma; AUC, area under the ROC curve; MAGI2-AS3, MAGI2 antisense RNA 3; ROC, receiver operating characteristic; SCC, squamous cell carcinoma; ZFAS1, ZNFX1 antisense RNA 1.](cmar-10-1449Fig2){#f2-cmar-10-1449}

![ARMS-PCR for *EGFR* intracellular mutations detection.\
**Notes:** (**A**), (**B**), (**C**) *EGFR* intracellular mutation cannot be detected in NO.6, NO.11, and NO.12 patient platelets. (**D**), (**E**), and (**F**) *EGFR* intracellular mutation can be detected in NO.6, NO.11, and NO.12 patient plasma.\
**Abbreviations:** ARMS, amplification-refractory mutation system; EGFR, epidermal growth factor receptor.](cmar-10-1449Fig3){#f3-cmar-10-1449}

![*EGFRvIII* expression in platelets and plasma derived from NSCLC patients.\
**Notes:** (**A**) *EGFRvIII* expression in 3 NSCLC platelets and plasma. (**B**) *GAPDH* expression as positive control in patients' platelets and plasma, three controls' results are shown here as an example. (**C**) No *EGFRvIII* expression in 50 healthy controls, and four individuals' results are shown here as an example. (**D**) *GAPDH* expression as positive control in healthy individuals' platelets and plasma. Four individuals' results are shown here as an example.\
**Abbreviations:** EGFR, epidermal growth factor receptor; NSCLC, non-small-cell lung cancer.](cmar-10-1449Fig4){#f4-cmar-10-1449}

![A schematic figure summarizing potential role of platelets in NSCLC.\
**Notes:** Platelets communicate with tumor cells through uptaking of tumor-associated biomolecules and thus may serve as a potential diagnostic marker for NSCLC.\
**Abbreviations:** AD, adenocarcinoma; NSCLC, non-small-cell lung cancer; SCC, squamous cell carcinoma.](cmar-10-1449Fig5){#f5-cmar-10-1449}

###### 

LncRNAs are screened out from three GEO datasets

  LncRNA         GEO dataset   Adenocarcinoma   Squamous cell carcinoma                                                                             
  -------------- ------------- ---------------- ------------------------- ---------- ------ ------- -------------- -------------- ---------- ------ ------
  MAGI2-AS3      GSE19188      0.921            0.863--0.980              \<0.0001   82.2   98.5    0.985          0.967--1.003   \<0.0001   100    87.7
  GSE30219       0.945         0.895--0.994     \<0.0001                  88.2       92.7   0.986   0.963--1.008   \<0.0001       98.4       92.9   
  GSE27262       0.972         0.947--1.012     \<0.0001                  100        92     −       −              −              −          −      
  LOC100507632   GSE19188      0.950            0.895--1.005              \<0.0001   100    84.4    0.992          0.979--1.004   \<0.0001   90.8   100
  GSE30219       0.968         0.926--1.010     \<0.0001                  92.9       91.8   0.993   0.980--1.006   \<0.0001       100        93.4   
  GSE27262       1.000         1.000--1.000     \<0.0001                  100        100    −       −              −              −          −      
  FOXF1-AS1      GSE19188      0.928            0.864--0.992              \<0.0001   93.9   91.1    0.989          0.972--1.005   \<0.0001   93.9   100
  GSE30219       0.945         0.876--1.015     \<0.0001                  85.7       96.5   0.972   0.936--1.008   \<0.0001       85.7       98.4   
  GSE27262       1.000         1.000--1.000     \<0.0001                  100        100    −       −              −              −          −      
  LOC100499467   GSE19188      0.887            0.809--0.9645             \<0.0001   96.9   82.2    0.995          0.987--1.003   \<0.0001   96.9   100
  GSE30219       0.857         0.740--0.9745    \<0.0001                  71.4       91.7   0.968   0.927--1.010   \<0.0001       85.7       96.7   
  GSE27262       0.992         0.977--1.007     \<0.0001                  96         96                            −                                
  ZFAS1          GSE19188      0.665            0.560--0.771              0.0033     64.4   64.6    0.660          0.527--0.793   0.016      63     69.2
  GSE30219       0.668         0.540--0.797     0.0436                    61.2       78.6   0.609   0.479--0.739   0.0497         57.4       78.6   
  GSE27262       0.781         0.644--0.9174    0.0007                    92         68     −       −              −              −          −      

**Abbreviations:** AUC, area under the ROC curve; GEO, gene expression omnibus; Se, sensitivity; Sp, specificity.

###### 

Correlation between MAGI2-AS3 and ZFAS1 level and clinical parameters of NSCLC

  Clinical parameters      Group      n    Platelet   MAGI2-AS3   *p*-value                                           Plasma   MAGI2-AS3   *p*-value                                           Platelet   ZFAS1   *p*-value                                           Plasma   ZFAS1   *p*-value
  ------------------------ ---------- ---- ---------- ----------- --------------------------------------------------- -------- ----------- --------------------------------------------------- ---------- ------- --------------------------------------------------- -------- ------- ---------------------------------------------------
  Histology                AD         68   32         36          0.480                                               33       35          0.778                                               35         33      0.394                                               34       34      0.886
  SCC                      33         18   15                     17                                                  16                   14                                                  19                 16                                                  17               
  Age                      \<60       48   22         26          0.482                                               21       27          0.271                                               24         24      0.776                                               19       29      0.058
  ≥60                      53         28   25                     29                                                  24                   25                                                  28                 31                                                  22               
  Gender                   Male       74   37         37          0.869                                               38       36          0.463                                               35         39      0.685                                               37       37      0.869
  Female                   27         13   14                     12                                                  15                   14                                                  13                 13                                                  14               
  Smoking                  Negative   40   16         24          0.122                                               18       22          0.327                                               18         22      0.567                                               19       21      0.774
  Positive                 61         34   27                     32                                                  29                   31                                                  30                 31                                                  30               
  TNM stage                I--II      25   5          20          0.001[a](#tfn2-cmar-10-1449){ref-type="table-fn"}   6        19          0.003[a](#tfn2-cmar-10-1449){ref-type="table-fn"}   6          19      0.005[a](#tfn2-cmar-10-1449){ref-type="table-fn"}   8        17      0.044[a](#tfn2-cmar-10-1449){ref-type="table-fn"}
  III--IV                  76         45   31                     44                                                  32                   43                                                  33                 42                                                  34               
  Invasion                 T1--T3     73   33         40          0.163                                               36       37          0.951                                               33         40      0.283                                               32       41      0.066
  T4                       28         17   11                     14                                                  14                   16                                                  12                 18                                                  10               
  Lymph--node metastasis   NO         36   12         24          0.016[a](#tfn2-cmar-10-1449){ref-type="table-fn"}   12       24          0.023[a](#tfn2-cmar-10-1449){ref-type="table-fn"}   17         19      0.847                                               17       19      0.733
  N1--N3                   65         38   27                     37                                                  28                   32                                                  33                 33                                                  32               
  Distant metastasis       MO         70   30         40          0.045[a](#tfn2-cmar-10-1449){ref-type="table-fn"}   30       40          0.045[a](#tfn2-cmar-10-1449){ref-type="table-fn"}   32         38      0.397                                               32       38      0.252
  MI                       31         20   11                     20                                                  11                   17                                                  14                 18                                                  13               

**Note:**

Overall *p*\<0.05.

**Abbreviations:** AD, adenocarcinoma; MAGI2-AS3, MAGI2 antisense RNA 3; NSCLC, non-small-cell lung cancer; SCC, squamous cell carcinoma; TNM, tumor--node--metastasis; ZFAS1, ZNFX1 antisense RNA 1.
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